{"id":59875,"date":"2024-02-28T06:21:37","date_gmt":"2024-02-28T06:21:37","guid":{"rendered":"https:\/\/medsname.com\/omez-d\/"},"modified":"2026-04-30T10:23:54","modified_gmt":"2026-04-30T10:23:54","slug":"omez-d","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/omez-d\/","title":{"rendered":"Omez D"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Omez D?<\/h3>\n

Omez D<\/strong> is a fixed-dose oral capsule combining a proton pump inhibitor (Omeprazole 20 mg)<\/strong> with the prokinetic dopamine antagonist domperidone 30 mg sustained-release<\/strong>. The PPI suppresses gastric acid secretion through irreversible inhibition of the parietal-cell H+\/K+-ATPase; domperidone speeds gastric emptying and tightens lower-oesophageal sphincter tone, which is useful when GERD is accompanied by regurgitation, gastroparesis, or functional dyspepsia<\/strong>. Neem 30–60 minutes before the first meal<\/strong>, swallow whole, do not crush the SR pellet. Manufactured by Dr. Reddy’s Laboratories under WHO-GMP standards.<\/p>\n<\/div>\n

Waarom bestellen bij MedsBase:<\/strong> \u2714 WHO-GMP gecertificeerde fabrikant<\/strong> \u2714 Discrete verpakking \u2714 Wereldwijde verzending \u2714 Geverifieerde klantbeoordelingen (1.400+ klanten)<\/a><\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n

Waarom bestellen bij MedsBase<\/h3>\n

Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen \u2014 geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor \u2014 nooit \u201cMedsBase\u201d of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.<\/p>\n

⚠️ EMA-restricted domperidone QT prolongation signal.<\/strong> Following a 2014 European review, domperidone is restricted to symptom relief of nausea\/vomiting at the lowest effective dose for the shortest duration (typically ≤ 7 days, max 30 mg\/day). Avoid in age > 60 unless benefits outweigh, in known QT prolongation, electrolyte disturbance (low K+\/Mg++), severe hepatic impairment, or with concurrent QT-prolonging or strong CYP3A4-inhibiting drugs (clarithromycin, ketoconazole, ritonavir). Hyperprolactinaemia and galactorrhoea may occur on prolonged use. Avoid in Parkinson’s disease (D2 antagonism worsens motor symptoms).<\/div>\n

When is the PPI + domperidone combination preferred over a PPI alone?<\/h2>\n

Plain PPI monotherapy (Omez, Pan, Razo etc.) is the standard for uncomplicated GERD or peptic ulcer. Adding domperidone helps when the dominant symptom is regurgitation<\/strong>, postprandial fullness<\/strong>, nausea<\/strong>, or when there is delayed gastric emptying<\/strong> (diabetic gastroparesis, post-vagotomy, idiopathic). For uncomplicated heartburn the simpler PPI is preferred — domperidone has a small but real cardiac signal that does not justify routine use.<\/p>\n

Waarom bestellen bij MedsBase<\/h3>\n

Omez D is supplied from a WHO-GMP gecertificeerde fabrikant<\/strong>. Elke bestelling wordt discreet wereldwijd verzonden en valt onder onze Reshipment Assurance Policy<\/a> — if it does not arrive within 20 business days, we reship at no cost. Omeprazole is one of the most prescribed PPIs worldwide and the SR-domperidone fraction adds gastric-emptying support without the IR-domperidone’s pulse-and-trough exposure profile.<\/p>\n

Werkingsmechanisme<\/h2>\n

Omeprazol<\/strong> is a substituted benzimidazole PPI that is activated by the acidic environment of the parietal-cell secretory canaliculus. Once activated it covalently binds Cys813 (and other cysteines) on the α-subunit of the H+\/K+-ATPase, irreversibly inhibiting acid secretion. Recovery requires synthesis of new pump protein (~24–48 h half-life of the pump itself).<\/p>\n

Domperidon<\/strong> is a peripheral dopamine D2 receptor antagonist that does not cross the blood-brain barrier in significant amounts (so it lacks the central D2-antagonism extrapyramidal signature of metoclopramide). In the gut it increases lower-oesophageal sphincter tone, accelerates gastric emptying, and improves antroduodenal coordination. It also blocks D2 receptors in the chemoreceptor trigger zone (which sits outside the BBB) producing antiemetic effect.<\/p>\n

Indicaties<\/h2>\n